Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05746481 · ClinicalTrials.gov registry record · Phase 2
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
A Phase 2 study, sponsored by Liza Villaruz, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05746481 is a Phase 2 study that was terminated before completion, run by Liza Villaruz, MD. The registered enrollment target is 3 participants.
The verdict
NCT05746481, a Phase 2 study, was terminated before completion, sponsored by Liza Villaruz, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients with asymptomatic untreated brain metastases.
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Pemetrexed
- DRUG Tiragolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-08-10 |
| Est. Completion | 2025-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05746481
The ClinicalTrials.gov registry entry for NCT05746481 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Liza Villaruz, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT05746481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05746481 about?
NCT05746481 is a clinical study titled "Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases". This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients with asymptomatic untreated brain metastases.
What is the current status of trial NCT05746481?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2023-08-10. Estimated completion is 2025-11-08.
What interventions are being tested in trial NCT05746481?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Pemetrexed (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT05746481?
This trial is sponsored by Liza Villaruz, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.